Francois Brisebois, an analyst from LifeSci Capital, maintained the Buy rating on Praxis Precision Medicines. The associated price target remains the same with $534.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Francois Brisebois has given his Buy rating due to a combination of factors related to Praxis Precision Medicines’ advancing CNS pipeline and upcoming data catalysts. He highlights that the company will present extensive new and expanded analyses at the 2026 AAN meeting, with particular emphasis on ulixacaltamide’s Essential3 Phase 3 program in essential tremor, including durability of response data showcased in a high‑visibility plenary session.
Brisebois also points to multiple poster presentations that further characterize ulixacaltamide’s efficacy and safety profile, which could strengthen its clinical and commercial positioning in ET. In addition, he underscores the breadth of the broader CNS pipeline, including forthcoming POWER1 Phase 2/3 data for vormatrigine this quarter and updates on relutrigine and elsunersen, viewing this rich cadence of near‑term catalysts as supportive of the stock’s upside potential despite the company’s substantial cash burn profile.
In another report released on April 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $1,245.00 price target.